Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
The Web's Daily Resource for PF News| Pulmonary Fibrosis News
The Web's Daily Resource for PF News| Pulmonary Fibrosis News
The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United Therapeutics, plans to use findings from the study and […] The post Tyvaso boosts lung function in IPF trial, per top-line data appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
First in a series. Shortly after I learned I had idiopathic pulmonary fibrosis (IPF) in January 2017, I came to rely on the Pulmonary Fibrosis Foundation (PFF) as a reliable source of information. That relationship continues today, more than four years after my bilateral lung transplant in 2021. I recently interviewed Scott Staszak, the PFF’s […] The post Talking with the Pulmonary Fibrosis Foundation CEO, part 1 appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
September is Pulmonary Fibrosis Awareness Month, and organizations around the world are gearing up to educate others and bring attention to pulmonary fibrosis (PF) — and also interstitial lung diseases (ILDs), which are disorders marked by scarring in the lungs. “We urgently need broader awareness because with it comes greater investment in research, faster diagnoses, […] The post Advocates: Urgent need for ‘broader awareness’ of pulmonary fibrosis appeared first on Pulmonary Fibros...| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
“Anticipation, anticipation/ Is makin’ me late/ Is keepin’ me waitin’.” The chorus of Carly Simon’s 1971 song “Anticipation” came to mind earlier this week as my wife, Susan, and I prepare to leave for vacation. Despite booking our trip through the Czech Republic, Germany, and France almost a year in advance, I can’t believe it’s […] The post What finalizing travel preparations as a post-transplant patient entails appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important milestone not only for Rein, but also […] The post UK approves Phase 2 trial for IPF therapy candidate LTI-03 appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.| Pulmonary Fibrosis News
There are more immune NK T-cells in the lungs of people with idiopathic pulmonary fibrosis than in healthy people, research shows| Pulmonary Fibrosis News
Margarida Maia is a science writer for Pulmonary Fibrosis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Consistently tracking the levels of Krebs von den Lungen-6 (KL-6), a protein that can indicate lung inflammation or damage, may help predict acute exacerbations in people with idiopathic pulmonary fibrosis (IPF) and other types of fibrotic interstitial lung diseases (ILDs), a study reports. Findings indicated that KL-6 levels tended to rise before an acute exacerbation […] The post KL-6 protein levels may predict symptom worsening in IPF: Study appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
When your time here on Earth is done, what will your legacy be? We all leave one behind, intentionally or unintentionally. What do you want to be remembered for? When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I’d already retired once from a successful career as a special agent for the […] The post We all leave a legacy, so be sure to shape yours with intention appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis of biomarker data from an ongoing Phase 2a clinical trial. “These 6-week interim biomarker data, while early and based on a small subset of participants, continue to […] The post GRI-0621 may reduce scarring in idiopathic pulmonary fibrosis: Trial appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Vanda Pinto is a science writer for Pulmonary Fibrosis News with a PhD in biomedicine. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Columnist Ann Reynoso explains that she's using Ozempic to manage several health issues, but also to hopefully qualify for a lung transplant.| Pulmonary Fibrosis News
While columnist Sam Kirton's quality of life improved after his lung transplant, the healing journey hasn't been easy, he says.| Pulmonary Fibrosis News
Looking for information about pulmonary rehabilitation for pulmonary fibrosis (PF)? Read about it here.| Pulmonary Fibrosis News
Learn more about the signs, symptoms and complications associated with the debilitating respiratory disease pulmonary fibrosis.| Pulmonary Fibrosis News
Learn more about the tests and examinations used to reach a diagnosis of pulmonary fibrosis, which is characterized by scarring in the lungs.| Pulmonary Fibrosis News
Read about the different factors that can cause pulmonary fibrosis.| Pulmonary Fibrosis News
Pulmonary fibrosis is taxing for patients and family. Palliative care aims to help patients live longer and better lives through treatment and assistance.| Pulmonary Fibrosis News
Learn more about Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).| Pulmonary Fibrosis News
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
Learn about familial pulmonary fibrosis, a rare form of pulmonary fibrosis, including its symptoms, diagnosis, risk factors, and treatment.| Pulmonary Fibrosis News
Esbriet (pirfenidone) is an oral treatment that has been approved by the U.S. Food and Drug Administration for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
Because certain IPF and post-transplant medications can cause sun sensitivity, skin protection is crucial, says columnist Sam Kirton.| Pulmonary Fibrosis News
A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.| Pulmonary Fibrosis News
During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
Nerandomilast slowed lung function decline in people with IPF and PPF after a year of treatment, according to data from two clinical trials.| Pulmonary Fibrosis News
LTI-03 is formulated as a dry powder inhalation therapy that's designed to help ease fibrosis and symptoms of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Category archive page for Columns.| Pulmonary Fibrosis News
After getting ill following a routine bronchoscopy procedure, columnist Sam Kirton learns he has a bacterial infection in his lungs.| Pulmonary Fibrosis News
For National Donate Life Month, columnist Sam Kirton urges readers to spread the word about the importance of being an organ donor.| Pulmonary Fibrosis News
Columnist Ann Reynoso says she's struggling to lose weight, but each step forward, no matter how small, is still progress.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News
